[A19-16] Daratumumab (multiple myeloma) - Addendum to Commission A18-66
Last updated 22.03.2019
Project no.:
A19-16
Commission:
Commission awarded on 12.03.2019 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adult patients with newly diagnosed multiple myeloma
Analysis of the first data cut-off for the total study population and subpopulation (not eligible for autologous stem cell transplant): both advantages and disadvantages versus appropriate comparator therapy
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A18-66 | Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2019-03-22 A G-BA decision was published.